Inventor · disambiguated record
Esther Latres
Also filed as: LATRES ESTHER
10 granted patents·12 pending applications·291 citations·filing 1999–2023
91Inventor score
Files withREGENERON PHARMA15UNIV NEW YORK3CHIAUR DAH SHIAM1CHIAUR DAH SHIARN1REGENERAN PHARMACEUTICALS INC1
Top patents by PatentIndex Score
22 records- 0197US8871209B2Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin AREGENERON PHARMA·Filed 2012·Granted Oct 28, 2014·125 cites·11 claims
- 0296US9260515B2Antibodies to human GDF8REGENERON PHARMA·Filed 2014·Granted Feb 16, 2016·86 cites·6 claims
- 0394US9718881B2Anti-Activin A antibodies and uses thereofREGENERON PHARMA·Filed 2014·Granted Aug 1, 2017·21 cites·44 claims
- 0491US8840894B2Antibodies to human GDF8STITT TREVOR·Filed 2011·Granted Sep 23, 2014·24 cites·5 claims
- 0587US10526403B2Anti-activin A antibodies and uses thereofREGENERON PHARMA·Filed 2017·Granted Jan 7, 2020·4 cites·43 claims
- 0687US10400036B2Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin AREGENERON PHARMA·Filed 2018·Granted Sep 3, 2019·4 cites·18 claims
- 0787US7632503B2Method of treating a muscle-related condition with modified IGF1 polypeptidesREGENERON PHARMA·Filed 2008·Granted Dec 15, 2009·7 cites·2 claims
- 0885US9890212B2Antibodies to human GDF8REGENERON PHARMA·Filed 2015·Granted Feb 13, 2018·4 cites·14 claims
- 0984US2024117027A1Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin aREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1080US2024067712A1Antibodies to human gdf8REGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1180US2023312699A1Anti-activin a antibodies and uses thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 1273US11655291B2Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or activin AREGENERAN PHARMACEUTICALS INC·Filed 2019·Granted May 23, 2023·0 cites·22 claims
- 1369US2021163583A1Anti-activin a antibodies and uses thereofREGENERON PHARMA·Filed 2020·Application pending·0 cites
- 1464US2015010568A1Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin aREGENERON PHARMA·Filed 2014·Application pending·0 cites
- 1562US6720181B1Ubiquitin ligases as therapeutic targetsUNIV NEW YORK·Filed 1999·Granted Apr 13, 2004·16 cites·12 claims
- 1662US2010212033A1Novel ubiquitin lifases as therapeutic tragetsCHIAUR DAH SHIAM·Filed 2008·Application pending·0 cites
- 1760US2019023777A1Antibodies to human gdf8REGENERON PHARMA·Filed 2018·Application pending·0 cites
- 1860US2017226197A1Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin aREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 1959US2017008956A1Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin aREGENERON PHARMA·Filed 2016·Application pending·0 cites
- 2050US2009292004A1Methods to identify compounds useful for the treatment of proliferative and differentiative disordersCHIAUR DAH SHIARN·Filed 2008·Application pending·0 cites
- 2147US2005251871A1Novel ubiquitin ligases as therapeutic targetsUNIV NEW YORK·Filed 2003·Application pending·0 cites
- 2245US2005079558A1Methods to identify compounds useful for the treatment of proliferative and differentiative disordersUNIV NEW YORK·Filed 2003·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →